Journal article
Breathing new insights into the role of mutant p53 in lung cancer
T Chen, LM Ashwood, O Kondrashova, A Strasser, G Kelly, KD Sutherland
Oncogene | Published : 2025
Abstract
The tumour suppressor gene p53 is one of the most frequently mutated genes in lung cancer and these defects are associated with poor prognosis, albeit some debate exists in the lung cancer field. Despite extensive research, the exact mechanisms by which mutant p53 proteins promote the development and sustained expansion of cancer remain unclear. This review will discuss the cellular responses controlled by p53 that contribute to tumour suppression, p53 mutant lung cancer mouse models and characterisation of p53 mutant lung cancer. Furthermore, we discuss potential approaches of targeting mutant p53 for the treatment of lung cancer.
Related Projects (1)
Grants
Awarded by University of Melbourne
Funding Acknowledgements
The authors thank Peter Maltezos for his expertise in preparing the figures. This study was supported by fellowships and grants from the Australian Health and Medical Research Council (NHMRC) (Programme Grant GNT1113133 to AS, Research Fellowship GNT 1116937 to AS, Ideas Grants GNT2002618 and GNT2001201 to GLK, Synergy Grants GNT 2011139 to GLK and GNT2010275 to OK, AS and KDS). GLK is supported by a Victorian Cancer Agency Mid-Career Fellowship. Research support was also provided by the estate of Antony (Toni) Redstone OAM (to AS and GLK), the Craig Perkins Cancer Research Foundation (to GLK), the Dyson Bequest (to GLK), the Harry Secomb Foundation (to GLK) and the Julie and Peter Alston bequest (to KDS). TC is the recipient of the Research Training Scholarship, The University of Melbourne. This work was made possible through Victorian State Government Operational Infrastructure Support (OIS) and Australian Government NHMRC Independent Research Institute Infrastructure Support (IRIIS) Scheme.